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Background: Adaptive servo-ventilation (ASV) therapy, which is a form of noninvasive positive pressure ventilation
therapy and uses an innovative ventilator that has simple operability and provides good patient adherence, potentially
has therapeutic benefits—suppression of the deterioration and progression of chronic heart failure (CHF) and a
reduction in the number of repeated hospitalizations. Therefore, ASV therapy draws attention as a novel, noninvasive
nonpharmacotherapy for patients with CHF owing to its hemodynamics-improving effect, and it is currently being
accepted in real-world clinical settings in Japan. However, clinical evidence sufficient for treatment recommendation is
lacking because a multicenter, randomized, controlled study of ASV therapy has never been conducted.
Methods/Design: The present study is a confirmatory, prospective, multicenter, collaborative, open-label, blinded-
endpoint, parallel-group, randomized, controlled study. At 40 medical institutions in Japan, 200 Japanese outpatients
with mild to severe CHF (age: ≥ 20 years; New York Heart Association classification: greater than or equal to class II) will
be randomly assigned to either of the following two study groups: the ASV group, in which 100 outpatients undergo
guideline-directed medical therapy and ASV therapy for 24 weeks; and the control group, in which 100 outpatients
undergo only guideline-directed medical therapy for 24 weeks. The objective of the present study is to confirm
whether the ASV group is superior to the control group concerning the improvement of left ventricular contractility
and remodeling, both assessed by two-dimensional echocardiography. Furthermore, the present study will also
secondarily examine the effects of ASV therapy on the prognosis and quality of life of patients with CHF.
Discussion: ASV therapy using the device has the potential to provide therapeutic benefits based on its simple
operability and good patient adherence and possesses the potential to improve left ventricular contractility and
remodeling. Therefore, the present study is expected to afford more solid scientific evidence regarding ASV therapy as
a novel, noninvasive, nonpharmacological, in-home, long-term ventilation therapy for patients with mild to severe CHF.
Trial registration: UMIN identifier: UMIN000006549, registered on 17 October, 2011.
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In recent years, pharmacotherapy for chronic heart failure
(CHF) has made remarkable progress. Furthermore, non-
pharmacotherapies (for example, cardiac resynchroniza-
tion therapy using an implantable cardioverter-defibrillator
and comprehensive cardiac rehabilitation) have shown a
given level of efficacy. However, patients with severe CHF
still have a poor life prognosis and are often and repeatedly
admitted to the hospital in the chronic clinical course of
the disease. In addition, there are many patients whose
symptoms of pulmonary congestion (for example, dyspnea
and orthopnea) as well as quality of life are not sufficiently
improved by existing therapeutic modalities.
Noninvasive positive pressure ventilation (NPPV) ther-
apy has been reported to improve not only dyspnea and
respiratory distress caused by cardiogenic pulmonary
edema but also cardiovascular hemodynamics [1]. Namely,
NPPV therapy is beneficial for both the respiratory and
hemodynamic functions of patients with heart failure. In
Japan, NPPV therapy is recommended for patients with
acute heart failure who do not respond to oxygen therapy
as a therapy categorized to class I in treatment recommen-
dation and to A in evidence level [2]. These facts lead us
to conjecture that NPPV therapy is potentially effective for
patients presenting with symptoms that are attributable to
the insufficient long-term management of pulmonary con-
gestion/edema (for example, dyspnea at rest, intense fatig-
ability, orthopnea, and paroxysmal nocturnal dyspnea).
Nevertheless, NPPV therapy has not become established
as a therapeutic modality for CHF because conventional
medical devices for NPPV therapy are difficult to use
for a long period due to their problems (for example,
cumbersome operability of the devices and poor patient
adherence).
Adaptive servo-ventilation (ASV) therapy, which is a
form of NPPV therapy and uses an innovative ventilator
AutoSet CS™ (Teijin Pharma Limited, Tokyo, Japan), po-
tentially has the following mechanistic features that differ
from conventional NPPV therapy including continuous
positive airway pressure and bi-level positive airway pres-
sure: 1) ASV therapy appropriately sustains ventilation by
instantaneously detecting a decay in spontaneous ventila-
tion of the patient and by providing support pressure in
concert with his/her respiratory flow patterns; and 2) ASV
therapy presents more physiological synchronization with
the respiratory patterns [3]. ASV therapy potentially has
therapeutic benefits—suppression of the deterioration and
progression of CHF and a reduction in the number of re-
peated hospitalizations—based on the simple operability
of the device and good patient adherence as compared
with conventional NPPV therapy. Thus, it draws attention
as a novel, noninvasive nonpharmacotherapy for patients
with CHF owing to its hemodynamics-improving effect.
Prior to the present study, we conducted a multicenter,retrospective, observational study [Study on the effects of
Adaptive servo-Ventilation In patients with chrOnic heart
failuRe: Real-world, multicenter, retrospective, observa-
tional study (SAVIOR-R)] for the objective of examining
the real-world practical efficacy and limitations of ASV
therapy for patients with CHF in Japan [4]. SAVIOR-R
suggested that ASV therapy possibly improves the cardiac
function and symptoms of patients with CHF, regardless
of the severity of sleep-disordered breathing. Furthermore,
prior single-center clinical studies indicated that ASV
therapy improves left ventricular contractility and induces
cardiac reverse remodeling [5], that pulmonary congestion
improved by positive end-expiratory pressure suppresses
sympathetic nerve activity [6-8], and that ASV therapy im-
proves left ventricular ejection fraction (LVEF) and re-
duces brain natriuretic peptide levels [9] and further
cardiac events (death and hospitalization) [10].
The present study is a confirmatory study of SAVIOR-R
and aims to assess the effects of ASV therapy on left ven-
tricular contractility and remodeling in patients with mild
to severe CHF in a multicenter, randomized, controlled
study. Left ventricular contractility and remodeling will be
assessed by two-dimensional echocardiography.
Methods/Design
Study design and study organization
The present study (SAVIOR-C) is a confirmatory, pro-
spective, multicenter, collaborative, open-label, blinded-
endpoint, parallel-group, randomized, controlled study.
The target number of patients is 200, and the study
groups consist of the ASV group and the control group.
The present study will last for 24 weeks, and the primary
and secondary endpoints will be assessed at baseline
(8 weeks prior to treatment onset through treatment
onset), at week 12 of study (±4 weeks), on the day of
study discontinuation, or on the day of study completion
at week 24 (±4 weeks).
The Steering Committee will perform activities (for ex-
ample, selection of study sites, investigators, and others,
preparation and revision of the protocol and other docu-
ments, interpretation of questions about the study plan,
coordination with investigators, establishment of the hand-
ling criteria for patients and data, determination of the ac-
ceptance of patients and data, interpretation of the study
results, and preparation of study conclusions; Additional
file 1). The Central Adjudication Committee will confirm
in a blind manner the absence of any problems in meas-
urement conditions and results of two-dimensional echo-
cardiographic parameters, including LVEF—the primary
endpoint—and in the subinvestigator’s assessment on CHF
deterioration—the secondary endpoint, and will check
whether adverse events and ventilator failure have de-
veloped in a biased fashion to a given group. The Study
Promotion Committee will afford study support to study
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Review Board at each participating medical institution
(Additional file 2) before its conduct in accordance with the
Declaration of Helsinki. Prior to enrollment, all patients will
provide written informed consent to be involved in the
present study. The present trial is registered (UMIN identi-
fier: UMIN000006549, registered on 17 October, 2011).
Patients
SAVIOR-C will assign 200 Japanese outpatients with CHF,
who meet all of the inclusion criteria and do not fall under
any of the exclusion criteria (Table 1), to either of the fol-
lowing two study groups at 40 medical institutions in
Japan based on assignment adjustment factors [age: < 65
years/≥ 65 years: gender: male/female:, and New York
Heart Association (NYHA) classification: class II/III]: the
ASV group and the control group (Figure 1).
Study treatment
Study treatment initiates within 8 weeks after provision
of the verbal and written explanations by the investigator
to each patient. Eligibility check, enrollment, and ran-
domization of each patient are performed between the
provision and the study onset. Patients in the ASV group
undergo ASV therapy in addition to guideline-directed
medical therapy [11] for the study period (study onset
through week 24 of study), while patients in the control
group undergo only guideline-directed medical therapy
for the study period. Patients in the ASV therapy group,Table 1 Inclusion and exclusion criteria
Inclusion criteria Ex
1. Men and women 1.
2. Age ≥20 years at informed consent acquisition - A
3. Patients with CHF who are undergoing guideline-directed medical therapy - S




5. Patients whose NYHA class at baseline* is greater than or equal to II - R









*Week 8 before enrollment through day of enrollment. ASV, adaptive servo-ventilat
New York Heart Association.who are in bed, undergo the ASV therapy each night
during the study period.
Endpoints
Efficacy, safety, and other aspects of ASV therapy will be
assessed. The primary endpoint for efficacy is LVEF, a vari-
able for the evaluation of heart failure that is applicable to
a randomized controlled study of prospective, open-label,
blinded-endpoint design. Two-dimensional echocardiog-
raphy will be conducted at each institution in accordance
with the procedures specified for SAVIOR-C. LVEF, left
ventricular end-systolic volume, and left ventricular end-
diastolic volume will be calculated according to the bi-
plane Simpson’s method [12]. Furthermore, the Central
Adjudication Committee will determine in a blinded fash-
ion the acceptability of the echocardiograms to be submit-
ted by the investigators.
The secondary endpoints for efficacy are 1) clinical
events (death, hospitalization, treatment changes, and
long-lasting (≥12 weeks) deterioration of symptoms) [13]
to be finally adjudicated by the Central Adjudication Com-
mittee in a blind fashion, 2) brain natriuretic peptide to be
measured at each participating medical institution, and 3)
clinical composite response to be categorized (worsened,
unchanged, and improved) based on NYHA classification
and clinical events.
The endpoints for safety are adverse events and venti-
lator failure. The endpoints for other aspects of ASV
therapy are as follows: 1) those to be collected via theclusion criteria
Patients with any of the following symptoms:
cute sinusitis or otitis media
ymptoms predisposing vomiting in the mask
ncapable of swallowing airway secretions
neumothorax or mediastinal emphysema
ecent cranial injury or surgery
hronic hypoventilation
Patients at risk of developing any of the following symptoms due to the
use of the ASV device
ypotension or a significant reduction in intravascular volume
ntense nasal bleeding leading to the risk of pulmonary aspiration
Patients incapable of giving voluntary consent
Patients with a history of undergoing the treatment of CHF by ASV at
home
Patients who are enrolled in another clinical study or trial
Patients diagnosed with or suspected of dementia
Patients whom the attending physician has considered ineligible for this
study
ion; CHF, chronic heart failure; LVEF, left ventricular ejection fraction; NYHA,
Outpatients with chronic heart failure: 200 
Assignment adjustment factors 
Age: < 65/≥ 65 years 
Gender: Male/female 
NYHA: II/III 
AHI: “< 15/h”/“≥ 15/h” 
Control group (n = 100) 
24-week GDMT only 
ASV group (n = 100) 
24-week GDMT and ASV therapy 
Observation, testing, and assessment (at study discontinuation or up to study completion) 
Enrollment 
Randomization
Figure 1 Flow diagram of SAVIOR-C. AHI, apnea-hypopnea index; ASV, adaptive servo-ventilation; GDMT, guideline-directed medical therapy;
NYHA, New York Heart Association.
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tivities of daily living, vital signs, physical findings, echo-
cardiograms, chest radiographs, hematology results, sleep
study results (for example, apnea-hypopnea index), and
usage of the ventilator, all from the ASV and controlTable 2 Schedule for observation, testing, and assessment
Acquisition means Examination items Timing (a
Baseline: w
through d
Case report form Patient background ×
Combined therapy ×
Symptoms (NYHA class and
self-assessment of daytime sleepiness)
×















Electronic means Echocardiogram ×
Air flow in the sleep study ×1
Usage of the ventilator in the
ASV group
1Without the ASV device, a device for sleep study (type 1, 2, or 3) is used. 2Without
ASV, adaptive servo-ventilation; NYHA, New York Heart Association.groups; and 2) those to be collected via electronic
means—echocardiograms and air flow in the sleep study
from the ASV and control groups, and usage of the venti-
lator from the ASV group. The schedule of observations,
examinations, and assessments is shown in Table 2.llowable range)




Day of study discontinuation
or day of study completion

















the ASV device, a device for sleep study (types 1, 2, 3, or 4) is used.
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The subgroup analysis of patients with reduced LVEF
(<40%) in SAVIOR-R revealed a 6.9% improvement (be-
fore ASV therapy: 26.5 ± 7.4%; after ASV therapy: 33.4 ±
13.0%). In SAVIOR-R, furthermore, a statistical analysis
considering time-course changes in LVEF indicated that
the LVEF-improving effect of ASV therapy tended to
appear at week 12 of the study or later. LVEF remained
unchanged when ASV therapy was not conducted and im-
proved by 5% when ASV therapy was conducted for 24
weeks. The target number of patients in SAVIOR-C was
calculated based on an assumed standard deviation of 7.4
in reference to the pre-ASV therapy value. Consequently,
power exceeds 80% when a group includes not less than
90 patients. Since sufficient power is obtained when a
group includes 100 patients in consideration of a pre-
sumed withdrawal rate of 10%, a total of 200 patients—
100 patients per study group—were established.
The efficacy analysis set consists of the full analysis set
and the per-protocol set to be defined below. The full
analysis set consists of patients who initiated ASV ther-
apy, from whom the following patients are excluded: 1)
patients in the ASV group who never used the ventilator
during the study period; and 2) patients from whom the
efficacy data after study onset were not obtained at all
during the study period. The per-protocol set consists of
patients in the full analysis set, from whom the following
patients are excluded: 1) patients who deviated from the
inclusion criteria or fell under any of the exclusion cri-
teria; 2) patients who fell under any of prohibited com-
bination therapies; and 3) patients with poor compliance
in ventilator use. Poor compliance is defined as an ASV
therapy practice rate of < 80% (number of days from day
of treatment onset through day of treatment discontinu-
ation or day of study completion). The safety of the study
groups will be analyzed statistically on an intention-to-
treat basis.
The aim of the statistical analyses is to examine the effi-
cacy and safety of ASV therapy for the target number of
200 patients by comparing the ASV group with the control
group with respect to the primary endpoint for efficacy—
LVEF—and to the measured values of respective second-
ary endpoints. The detailed procedures for randomized as-
signment will be determined but will not be informed to
the subinvestigators at each participating medical institu-
tion. The details and technical methods of the statistical
analyses will be described in the statistical analysis plan to
be prepared prior to database lock. Statistical tests (for ex-
ample, chi-square test using the contingency table, Fisher’s
exact probability test, Kruskal-Wallis test, and analysis of
variance) will be used in accordance with the scale of
demographic data. Furthermore, a two-tailed probability
of 15% will be established as an index of intergroup homo-
geneity. The data to be collected in the present study willbe analyzed by the Japan-Clinical Research Support Unit
that is completely independent from study organizations.
Discussion
The 5-year survival rates of patients with CHF in the
1990s were as low as 25% and 38% for males and fe-
males, respectively [14]. The 5-year survival rate of pa-
tients with CHF who had left ventricular systolic
dysfunction improved to 52% [15]. However, in both
males and females, CHF requiring hospitalization was
more “malignant” than many of the common types of
cancer [16]. The 5-year survival rates of patients with
CHF aged 65 to 74 years were 54% and 40% for males
and females, respectively [17]. Furthermore, the 5-year
survival rates of patients with CHF categorized to stages
A, B, C, and D were 97%, 96%, 75%, and 20%, respect-
ively [18]. These epidemiologic data clearly indicate that
CHF, once progressed, still exhibits a poor life prognosis
despite recent progress in therapeutic modalities and
that preventing the deterioration and progression of
CHF severe enough to require hospitalization is critically
important for the further betterment of the survival rate
of patients with CHF, and also indicates the need to de-
velop a novel therapeutic modality which is useful for
the prevention and progression of CHF, apart from phar-
macotherapies and nonpharmacoptherapies that are rec-
ommended by guidelines [11,19,20].
Nonpharmacotherapies that are currently applied to the
treatment of CHF include 1) cardiac resynchronization
therapy using an implantable cardioverter-defibrillator to
treat heart failure involving dyssynchrony of left ventricular
contraction [21-23], 2) comprehensive cardiac rehabilita-
tion including exercise therapy [24-26], 3) Waon therapy—
soothing warmth therapy, a novel systemic treatment for
heart failure by means of dry far-infrared radiation sauna
equipment [27,28], 4) surgical approaches including coron-
ary revascularization [29], on- or off-pump coronary artery
bypass grafting [30], mitral annuloplasty [31], and mitral
valve replacement [32] to treat functional mitral regurgita-
tion caused by left ventricular volume expansion due to left
ventricular remodeling, 5) auxiliary circulation including
intraaortic balloon pumping [33] and extracorporeal auxil-
iary artificial heart [34], and 6) heart transplantation [35].
Nevertheless, none of these therapeutic modalities are
practicable at home, and all of them cause great physical,
mental, and economic burdens to the patient. The esti-
mated medical cost of pharmacotherapy for the treatment
of heart failure in the United States is $3.2 billion annually,
and about three-quarters of the total treatment costs for
heart failure are related with admissions to the hospital, in-
hospital treatment, and nursing care in nursing homes
[36]. Heart failure accounts for 56% of causes of death for
patients with NYHA class IV, while sudden death (for ex-
ample, fatal ventricular arrhythmias) accounts for 64% and
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and III, respectively [37]. In Japan, furthermore, the per-
centages of patients categorized to NYHA classes I to IV at
admission were 1.2%, 11.4%, 44.6%, and 42.9%, respectively
[2]. Therefore, it is vitally important in the therapeutic
strategy and medical economics of CHF to reasonably re-
duce the percentages of NYHA class III and IV patients, as
well as the number of repeated admissions to hospital.
Positive end-expiratory pressure generated by NPPV
therapy has the following physiologic mechanisms: allevi-
ation of preload via a decrease in venous return [38], sup-
pression of sympathetic overactivity [6,7], and relief of
afterload via a reduction in transmural pressure [39,40].
The activation of these mechanisms is also expected dur-
ing in-home therapy for the treatment of CHF. Neverthe-
less, conventional NPPV therapy has the limitations of
cumbersome operability of the ventilator and poor patient
adherence, and has not sufficiently diffused as a thera-
peutic modality for CHF that brings therapeutic benefits.
AutoSet CS™, originally developed for the treatment of
sleep-disordered breathing, demonstrates extensive im-
provements in the abovementioned drawbacks of the con-
ventional medical devices for NPPV therapy. ASV therapy
is being accepted rapidly among Japanese cardiologists
who expect the circulatory and respiratory function-
improving effects of the device. SAVIOR-R, which investi-
gated the practice efficacy and limitations of ASV therapy
for real-world patients with CHF in Japan, clearly revealed
these facts and also suggested, as with other prior studies
[9,10], that ASV therapy improves the cardiac function of
patients with CHF, regardless of the severity of sleep-
disordered breathing. The present study plans to investigate
these expectations in terms of the multicenter, randomized,
controlled study because of its confirmatory nature of
SAVIOR-R.
ASV therapy has the potential to improve left ventricu-
lar contractility via reverse remodeling, exerting thera-
peutic benefits based on the simple operability of the
device and good patient adherence as compared with con-
ventional NPPV therapy, and improving the prognosis and
quality of life of patients with CHF. Therefore, the present
study is expected to afford more solid scientific evidence
about ASV therapy as a novel, noninvasive, nonpharmaco-
logical, in-home, long-term ventilation therapy for patients
with CHF.
Trial status
The trial is ongoing.
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